Stockscreener 앱 받기
56.80
1.03%
0.58
시간 외 거래:
57.09
0.29
+0.51%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - Benzinga
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer - Pharmaceutical Technology
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Swiss National Bank - MarketBeat
Kinsale Capital Group Inc. Purchases 18,163 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Mizuho Markets Americas LLC Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Kentucky Retirement Systems Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb (NYSE:BMY) Trading Down 3%Here's Why - MarketBeat
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - BioSpace
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue - Benzinga
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims - FiercePharma
BMYBristol-Myers Squibb Co. Latest Stock News & Market Updates - StockTitan
Cornercap Investment Counsel Inc. Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Now Covered by Analysts at Wolfe Research - MarketBeat
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug - MSN
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug - Reuters
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Justice on the Move: The Impact of Bristol-Myers Squibb on FLSA Forum-Shopping - The National Law Review
9,269 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by Sargent Investment Group LLC - MarketBeat
Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Stake Lessened by KBC Group NV - MarketBeat
Plato Investment Management Ltd Purchases 13,447 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Clinical trials & studies - Bristol Myers Squibb
Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024 - Indian Pharma Post
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
ICICI Prudential Asset Management Co Ltd Sells 38,500 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now? - Insider Monkey
Oppenheimer & Co. Inc. Raises Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink - FiercePharma
Pinnacle Financial Partners Inc Acquires 272,439 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Mengis Capital Management Inc. Has $3.37 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Aigen Investment Management LP Sells 102,823 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Equities Analysts Issue Forecasts for BMY Q4 Earnings - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Upgraded by Leerink Partnrs to "Strong-Buy" Rating - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $60.00 at Citigroup - MarketBeat
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Bristol-Myers Squibb's $14 Billion PotentialAnalyst Upgrades Stock - Benzinga
BMO Capital Markets Boosts Bristol-Myers Squibb (NYSE:BMY) Price Target to $61.00 - MarketBeat
AbbVie’s loss is Bristol Myers Squibb’s gainanalyst - Proactive Investors USA
American Assets Inc. Purchases New Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers gets stock price target boost, rating held on Cobenfy outlook - Investing.com
Morgan Stanley Raises Bristol-Myers Squibb (NYSE:BMY) Price Target to $39.00 - MarketBeat
Why AbbVie’s disappointing schizophrenia drug trial bodes well for Bristol Myers - MarketWatch
Bristol-Myers upgraded at Leerink after AbbVie setback - MSN
Bristol-Myers Squibb (NYSE:BMY) Upgraded at Leerink Partners - MarketBeat
Bristol-Myers stock upgraded at Leerink (BMY:NYSE) - Seeking Alpha
Buy, Sell, Or Hold BMY Stock? - Forbes
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials - Clinical Trials Arena
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Entropy Technologies LP - MarketBeat
Atria Investments Inc Has $6.62 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Gets RS Rating Upgrade - Investor's Business Daily
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat - Morningstar
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
Bristol Soars 11% As Investors Question AbbVie's Costly 'Mistake' - Investor's Business Daily
Bristol-Myers Squibb (NYSE:BMY) Shares Up 12.4%Here's What Happened - MarketBeat
AbbVie tumbles on drug test disappointment, Bristol-Myers gains - Yahoo Finance
Trending : Bristol-Myers Squibb Shares Up on Setback for AbbVie Schizophrenia Drug - Marketscreener.com
Bristol Myers Stock Trading Near 52-Week High: Time To Buy Or Sell? - Barchart
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell? - Yahoo Finance Australia
What's Going On With Bristol-Myers Squibb Shares Monday? - Benzinga
1.13%
1.71%
자본화:
|
볼륨(24시간):